Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 40Breast Neoplasms, Male 12Urinary Bladder Neoplasms 5Stomach Neoplasms 5Rectal Neoplasms 5Pancreatic Neoplasms 5Inflammatory Breast Neoplasms 5Esophageal Neoplasms 5Endometrial Neoplasms 5Colonic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Neoplasms 4Uterine Cervical Neoplasms 3Urethral Neoplasms 3Thyroid Neoplasms 3Salivary Gland Neoplasms 3Prostatic Neoplasms 3Lung Neoplasms 3Gallbladder Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Bile Duct Neoplasms 3Vulvar Neoplasms 2Vipoma 2Vaginal Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 2Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Testicular Neoplasms 2

Interventions

trastuzumab biosimilar HLX02 1Trastuzumab 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Bladder Urothelial Carcinoma × Trastuzumab × Clear all
NCT00238420 2022-07-19

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 10 charts
Genitourinary

Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡